Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mannoheptulose is a naturally occurring seven-carbon monosaccharide (heptose) and ketose found in plants such as avocados, alfalfa, figs, and primrose. It acts as a competitive and non-competitive inhibitor of both hexokinase and glucokinase enzymes. By blocking these enzymes, mannoheptulose prevents the phosphorylation of glucose to glucose-6-phosphate—the first step in glycolysis—thereby inhibiting glucose breakdown. This inhibition also leads to reduced insulin secretion from pancreatic beta cells because ATP production is diminished, which disrupts the closure of KATP channels required for insulin release. Mannoheptulose has been studied primarily as a research tool in carbohydrate metabolism and for its potential use as a nutraceutical for weight management in dogs; however, evidence regarding its efficacy on energy expenditure is mixed[1][2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mannoheptulose.